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a r t i c l e s
Sepsis is characterized by arterial hypotension and the systemic inflammatory response syndrome 1 . The associated increase in circulating proinflammatory cytokines, including interferon-γ (IFN-γ), leads to the unchecked production of effector molecules, such as reactive oxygen and nitrogen species, that can contribute to pathology 1 . Nitric oxide (NO) is one such effector molecule. Synthesis of large amounts of NO by inducible nitric oxide synthase (NOS2) is implicated in the hypotension that accompanies sepsis 2 . This pathological situation contrasts with normal vascular homeostasis, in which small amounts of NO formed by endothelial nitric oxide synthase relax blood vessels 3 . IFN-γ and lipopolysaccharide (LPS) both induce NOS2 in vascular cells 4 , generating excessive NO, which results in profound vasodilation with hypotension. Treatment with NO synthesis inhibitors improves hemodynamic parameters in animal models of endotoxemia 5 . Mice lacking Nos2 are largely, but not completely, protected from LPSinduced hypotension 6 .
Increased production of NO also has been observed in human sepsis 7 . Inhibition of NO synthesis can promote the resolution of shock and temporarily improve hemodynamic variables, including an increase in mean arterial blood pressure 8 . However, inhibition of NO synthesis does not improve 28-d survival 8 or consistently yield long-term benefits to vascular health 9 . Therapies aimed at targets other than NOS2 also have failed to improve outcomes 1 .
The above findings, along with a recent report showing the role of endothelial nitric oxide synthase in anaphylactic shock 10 , indicate that additional pathways may be involved in the regulation of vascular tone during acute systemic inflammation. In this regard, it is noteworthy that the metabolism of arginine to NO, initiated by NOS2, is functionally related to the metabolism of tryptophan, initiated by Ido (Supplementary Fig. 1 ). Both pathways are implicated in antimicrobial activities, antitumor defense, neuropathology and immune regulation 11 . Similarly to Nos2, Ido is not normally expressed in cells 12 and requires induction via IFN-γ 13 or tumor necrosis factor-α. Once its expression has been induced, Ido converts tryptophan to N-formyl-kynurenine, which decomposes spontaneously to formate and kynurenine. Depending on the cell type involved, kynurenine may be metabolized further along the kynurenine metabolic pathway (Supplementary Fig. 1 ).
Despite this functional similarity between Nos2 and Ido, a direct vasomotor regulatory role for kynurenine pathway metabolites has not been previously identified. During systemic inflammation, vascular endothelial cells are the primary site for Ido expression in vivo 14, 15 . Furthermore, IFN-γ induces Ido in vitro in various vascular cells 16, 17 . We therefore examined the induction and potential function of Ido and tryptophan metabolism in blood vessels under conditions of systemic inflammation.
Kynurenine is an endothelium-derived relaxing factor produced during inflammation
RESULTS

Ido contributes to the regulation of blood pressure
We first tested the role of Ido in the regulation of blood pressure in C57BL/6J mice infected with Plasmodium berghei ANKA (PbA). PbA infection leads to systemic inflammation 18 and induces the expression of Ido protein in vascular endothelial cells 14, 15, 19 . We detected Ido expression in resistance vessels, such as renal arterioles, as assessed by immunohistochemistry 5 d after infection (Fig. 1a-c) . Expression of Ido was predominantly in endothelial cells 19 (Fig. 1a) . Systemic Ido expression translated into functional activity, as PbA infection resulted in significantly decreased plasma concentrations of tryptophan ( Fig. 1d) and significantly increased plasma concentrations of kynurenine (Fig. 1e) . PbA infection also resulted in hypotension (Fig. 1f) , which is known to be associated with severe and cerebral malaria in humans 20 and mice 21 . Administration of the selective Ido inhibitor 1-methyl-d-tryptophan (1-Me-Trp) 22 restored normal systolic blood pressure (SBP) in infected mice but had no effect on SBP in uninfected mice (Fig. 1f) . These results show that Ido is functionally important for the hypotension induced by PbA infection.
We next tested the role of Ido in the regulation of blood pressure in mice during PbA infection by using mice lacking Ido. Infection had no significant impact on plasma concentrations of tryptophan and kynurenine in Ido1 −/− mice (Fig. 1d,e) , and infusion of 1-Me-Trp failed to increase SBP in infected Ido1 −/− mice (Fig. 1g) or in infected mice lacking IFN-γ (Ifng −/− mice) (Supplementary Fig. 2 ), which do not express endothelial Ido 19 . We observed similar results when we measured blood pressure intra-arterially in unconscious mice as an alternate method (Supplementary Fig. 2 ). Despite the functional importance of Ido in regulating blood pressure in infected wild-type mice, as shown using 1-Me-Trp (Fig. 1f) , infection resulted in hypotension in Ido1 −/− mice (Fig. 1g) . As redundant mechanisms control blood pressure 23, 24 and the Ido-and Nos-initiated pathways interact with each other 11 , we compared the relative contribution of Nos to the regulation of blood pressure in wild-type versus Ido1 −/− mice. In uninfected mice, administration of the Nos inhibitor N ω -nitro-larginine methyl ester (l-NAME) increased blood pressure similarly in both types of mice, whereas l-NAME increased blood pressure to a greater extent in infected Ido1 −/− mice compared to wild-type mice (Supplementary Fig. 3 ). Separate studies with Nos2 −/− mice confirmed that Nos2 contributes to the regulation of blood pressure in PbA-infected mice ( Supplementary Fig. 4 ). Together these results suggest that Nos2 compensates for Ido in the regulation of blood pressure in PbA-infected Ido1 −/− mice.
We next tested the role of Ido in blood pressure regulation in two additional models of systemic inflammation: infection with P. berghei K173 (PbK), a strain of malaria that causes severe disease but no cerebral complications 25 , and endotoxemia. As was the case in PbAinfected mice, Ido was expressed in endothelial cells of resistance vessels from mice infected with PbK ( Supplementary Fig. 5a ,b) or mice suffering from endotoxemia ( Fig. 2a-d) . This induction of expression again translated into functional enzyme activity, as shown by changes in plasma tryptophan and kynurenine concentrations ( Fig. 2e and Supplementary Fig. 5c ), and was associated with hypotension ( Fig. 2f and Supplementary Fig. 5d ). Additionally, infusion of 1-Me-Trp restored normal SBP in endotoxemic (Fig. 2f) and PbK-infected mice (Supplementary Fig. 5d ).
In contrast with PbA infection, endotoxemia-induced hypotension was attenuated in Ido1 −/− mice at an early timepoint (74.3 ± 1.5 mm Hg versus 81.9 ± 1.7 mm Hg at 16 h after LPS treatment in wild-type versus Ido1 −/− mice, P < 0.01). However, at later stages of endotoxemia, as SBP returned to normal values in both Ido1 −/− and wild-type mice, SBP values were comparable in the two strains of mice (Fig. 2g) . The kinetics of the changes in SBP and the changes in the ratio of the plasma concentrations of kynurenine and tryptophan were the same ( Fig. 2h and Supplementary Fig. 6 ). Tissue Ido1 messenger RNA expression, as measured in the kidney, was induced 2 h after LPS injection and reached maximal levels at 5-10 h after LPS injection (Supplementary Fig. 7) . Furthermore, pharmacological inhibition of Ido immediately before or up to 8 h after LPS injection attenuated the extent of hypotension (Fig. 2i) . As Nos2 participates in LPS-induced hypotension in mice, we determined the effect of Ido inhibition in Nos2 −/− versus wild-type mice. LPS significantly lowered SBP in both types of mice (Fig. 2j) . Although the extent of hypotension was more pronounced in wild-type compared with Nos2 −/− mice, the relative contribution of Ido to this decrease in SBP was comparable in the two strains of mice (Fig. 2j) .
To confirm the role of Ido in the regulation of blood pressure, we wished to measure blood pressure using telemetry instead of the tail-cuff method, as the former is commonly considered the 'gold standard' method. However, implantation of the transmitter required for telemetry itself represented an inflammatory challenge to the Fig. 8 ).
We therefore compared mean arterial pressure (MAP) in transmitterimplanted wild-type versus Ido1 −/− mice. MAP was higher in Ido1 −/− compared with wild-type mice (Supplementary Fig. 9 ). These results, based on several models of systemic inflammation, together indicate that Ido contributes to the regulation of blood pressure, such that Ido inhibition or deficiency can ameliorate hypotension in the setting of systemic inflammation.
Endothelial Ido converts tryptophan to kynurenine
Consistent with previous observations that IFN-γ is a principal inducer of Ido in malaria-infected mice in vivo 26 and in various cell types in vitro 13 , we found that IFN-γ induced Ido1 mRNA ( Supplementary  Fig. 10 ) and Ido protein expression in porcine aortic endothelial cells in a dose-and time-dependent manner (Fig. 3) . IFN-γ also induced Ido activity (Fig. 3b,d ). Ido remained active for at least 48 h, as judged by the accumulation of kynurenine in the cell culture medium (Fig. 3d) . Consumption of tryptophan resulted in near stoichiometric accumulation of kynurenine (Fig. 3b,d ), indicating that kynurenine is the major tryptophan-derived metabolite produced by IFN-γ-treated porcine aortic endothelial cells. We obtained comparable results with IFN-γ-treated human umbilical vein cells (Supplementary Fig. 11 ) and rabbit aortic endothelial cells (data not shown). Therefore, induction of Ido is probably a general response of endothelial cells to this proinflammatory cytokine.
IFN-γ also induced Ido activity in a dose-and time-dependent manner in isolated porcine coronary arteries, which caused the luminal concentration of kynurenine to reach the millimolar range ( Fig. 3e) . We did not detect other kynurenine pathway metabolites, such as 3-hydroxykynurenine, kynurenic acid, 3-hydroxyanthranilate or quinolinic acid (data not shown). IFN-γ-induced kynurenine originated predominantly from endothelial cells, as removal of the endothelium decreased the amount of accumulated kynurenine by ~65% (from 1.20 ± 0.20 mM to 0.40 ± 0.03 mM, P < 0.01) (Fig. 3f) . Kynurenine production required active Ido, as inclusion of 1-Me-Trp (1 mM) during IFN-γ pretreatment prevented kynurenine accumulation (Fig. 3f) . Thus, IFN-γ-induced tryptophan metabolism by coronary arteries is restricted mostly to endothelial cells, and these cells are primarily responsible for the production of large quantities of kynurenine.
Tryptophan to kynurenine conversion regulates vascular tone
The addition of tryptophan to preconstricted porcine coronary arteries resulted in their relaxation (Fig. 4a) . This response depended on Ido activity, as it required IFN-γ to be present during the 20-h pretreatment of the arteries, and 1-Me-Trp inhibited relaxation induced by tryptophan (Fig. 4a) . Arteries pretreated with IFN-γ and incubated in the presence of 1-Me-Trp responded normally to the NO-generating drug sodium nitroprusside (10 µM) (96.5% ± 2.1% relaxation compared with that seen with arteries before pretreatment, n = 4), indicating that Ido inhibition does not affect the response to endothelium-independent vasodilators. Removal of the endothelium greatly lessened the relaxation of IFN-γ-pretreated vessels in response to tryptophan (Fig. 4a) . These data suggest that Idomediated, endothelium-dependent metabolism of tryptophan produces arterial relaxation. As endothelial Ido effectively metabolized tryptophan to kynurenine, we next examined whether kynurenine could directly modulate vascular tone. Indeed, kynurenine significantly attenuated the contractile response of porcine coronary arteries to the thromboxane analog U-46619 (Fig. 4b) , as indicated by the rightward shift of the dose-response curve. We obtained similar results with rabbit aortic rings (Supplementary Fig. 12 ). Furthermore, kynurenine relaxed preconstricted porcine coronary arteries (Fig. 4c) , rabbit aorta ( Supplementary Fig. 13 ) and mouse abdominal aorta (data not shown) in a dose-dependent manner, a response that did not require an intact endothelium. We observed relaxation at kynurenine concentrations of ≥300 µM (Fig. 4c) , which corresponds to concentrations achieved in vivo in cerebral blood vessels of PbA-infected mice 26 and ex vivo in IFN-γ-treated porcine coronary arteries (Fig. 3e,f) . In contrast, formate (≤5 mM), tryptophan, kynurenic acid, 3-hydroxykynurenine, 3-hydroxyanthranilic acid (all ≤1 mM) or quinolinic acid (≤0.1 mM) were ineffective in dilating vessels ( Supplementary  Fig. 14) . We observed similar results to those in porcine coronary arteries with rabbit and mouse aorta treated with kynurenine and related metabolites (data not shown), indicating that kynurenine has specific vessel-relaxing properties that probably extend to multiple types of vascular beds. We next tested the effects of kynurenine on blood pressure in vivo. Intravenous infusion of kynurenine caused a transient decrease in the mean arterial blood pressure of spontaneously hypertensive rats, similar to the effect of sodium nitroprusside (used as a positive control) (Fig. 4d) . In contrast, infusion of tryptophan up to a 5-mM final plasma concentration did not affect MAP (Fig. 4d) . Both kynurenine and sodium nitroprusside, but not tryptophan, lowered MAP in a concentration-dependent manner (Fig. 4e) .
Kynurenine relaxes blood vessels by activating guanylate cyclase
Having established kynurenine as an endothelium-derived vasodilator, we next asked how it relaxes blood vessels. By examining known pathways involved in the regulation of vascular tone, we found that kynurenine activates the cGMP-dependent pathway, as indicated by its ability to activate purified rat soluble guanylate cyclase (sGC) (Fig. 5a) and to increase tissue concentrations of cGMP (Fig. 5b) . Furthermore, Rp-8-CTP-cGMPS (10 µM), a protein kinase G (PKG) inhibitor, attenuated kynurenine-induced relaxation of porcine coronary arteries (Fig. 5c) .
Further detailed mechanistic studies on the ability of kynurenine to activate sGC were prompted by the unexpected observation that 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), an inhibitor of sGC, failed to inhibit the kynurenine-induced increase in cGMP in porcine coronary arteries (Fig. 5b) and the kynurenine-induced relaxation of these vessels (Fig. 5c) and of rabbit aorta ( Supplementary  Fig. 15 ). In fact, ODQ enhanced the kynurenine-induced increase in aortic cGMP concentrations (Fig. 5b) . This interaction between ODQ and kynurenine is similar to that previously reported between ODQ and BAY 58-2667 (cinaciguat), a blood pressure-lowering agent capable of selectively activating the oxidized or heme-free form of sGC via binding to the enzyme's heme binding site 27, 28 . For NO to activate sGC, its heme must be in its reduced state. ODQ oxidizes heme such that the enzyme becomes refractory to activation by NO 27 . Kynurenine activated heme-containing and heme-free purified rat sGC with equal efficacy; whereas, as expected, NO activated only the heme-containing enzyme (Fig. 5a) . Kynurenine-dependent activation of heme-containing, purified sGC was enhanced significantly by the presence of ODQ (Fig. 5d) . Together these data explain our observations that ODQ did not inhibit the effects of kynurenine on increasing cGMP concentrations and inducing vessel relaxation.
To confirm the role of sGC in kynurenine-induced vessel relaxation, we pretreated porcine coronary arteries with ODQ (10 µM) for 24 h at 37 °C to downregulate sGC expression 29 before functional studies. This pretreatment lowered the β subunit content of sGC (Fig. 5e) and also significantly decreased vessel relaxation in response to either the NO-donor DEA-NO (Fig. 5f) or kynurenine (Fig. 5g) . NO induces phosphorylation of Ser239 on vasodilator-stimulated phosphoprotein (VASP) in platelets through sGC and PKG signaling 30 . Consistent with the hypothesis that kynurenine activates sGC and PKG signaling, kynurenine stimulated VASP Ser239 phosphorylation in washed human platelets, similar to the effect of NO (Fig. 5h) .
Kynurenine activates adenylate cyclase
Kynurenine also activates the cAMP pathway, as indicated by its ability to increase the activity of adenylate cyclase enriched from porcine coronary arteries (Fig. 6a) . Furthermore, kynurenine increased the cAMP content in these arteries (Fig. 6b) and in rat aortic smooth muscle cells (Fig. 6c) , as well as the phosphorylation of VASP Ser157 in washed human platelets (Fig. 6d) and human MEG-01 cells (Fig. 6e) . Ser157 phosphorylation was measured as a readout of cAMP signaling, as compared to Ser239 being a readout of cGMP signaling 30 . The adenylate cyclase inhibitor SQ22,536 (100 µM) attenuated kynurenineinduced relaxation of porcine coronary arteries (Fig. 6f) , indicating the functional importance of adenylate cyclase activation by kynurenine. In contrast, inhibition of protein kinase A (PKA) with Rp-8-CTP-cAMPS (30 µM) (Fig. 6f) , H-89 (10 µM) (Fig. 6g) or KT 5720 ( Supplementary Fig. 16 ) had no material effect on kynurenineinduced vessel relaxation. However, kynurenine did induce PKA activity in platelets, as VASP Ser157 phosphorylation induced by kynurenine was inhibited by H-89 (Fig. 6e) . H-89 significantly attenuated forskolin-induced relaxation of mouse aortic rings (Fig. 6h), showing the ability of H-89 to block PKA-dependent effects in this preparation. These data, together with a previous report by others showing that cAMP can have cellular effects via PKG 31 , suggest that activation of adenylate cyclase by kynurenine contributes to vessel relaxation via a cAMP-dependent and PKA-independent pathway (Fig. 6i) .
DISCUSSION
Vascular endothelial cells synthesize vasodilators such as NO, prostacyclin, hydrogen peroxide, carbon monoxide and epoxyeicosatrienoic acids, as well as vasoconstrictors such as thromboxane A 2 , prostaglandin H 2 and endothelin-1. These substances have key roles in the local regulation of vascular tone and blood pressure. Our results indicate that tryptophan metabolism to kynurenine via the action of Ido is a previously undescribed endothelium-dependent pathway contributing to vascular relaxation and the regulation of blood pressure in systemic inflammation. Several lines of evidence support our contention that Ido can contribute to blood pressure regulation. First, Ido is expressed in endothelial cells of resistance vessels of mice that were hypotensive as a result of systemic inflammation, and in these mice inhibition of Ido using 1-Me-Trp restored normal blood pressure. Second, 1-Me-Trp had no effect on blood pressure in mice in the absence of inflammation or in mice suffering from inflammation but deficient in Ido or in IFN-γ and thus not expressing Ido 19 . Third, administration of the Ido product, kynurenine, decreased arterial blood pressure in hypertensive rats, relaxed preconstricted arteries and attenuated vessel constriction. Fourth, addition of the Ido substrate, tryptophan, to arteries expressing active Ido caused their relaxation, and this effect was inhibited by 1-Me-Trp.
In the models of systemic inflammation used, Ido induction occurred predominantly in vascular endothelial cells, indicating that they represent a major source of Ido activity in vivo. Circulating concentrations of key proinflammatory cytokines, including IFN-γ, increase in systemic inflammation 18 . IFN-γ is a principal inducer of Ido1 in various cell types, including those of the blood vessel wall 16 . Consistent with this previous report, we found that IFN-γ treatment causes a time-and dose-dependent induction of Ido1 in endothelial cells of different species, which was associated with the conversion of tryptophan to kynurenine. Therefore, Ido-mediated formation of kynurenine might contribute to the regulation of vascular tone in many types of inflammatory conditions. Our findings that kynurenine treatment lowered blood pressure in hypertensive rats and that kynurenine activated purified sGC suggest that kynurenine itself is the vasoactive metabolite of tryptophan. The concentrations of kynurenine required to achieve these biological activities are in the high micromolar to low millimolar range. Such concentrations accumulate in the lumen of both IFN-γ-treated porcine coronary arteries and cerebral blood vessels of mice infected with PbA 26 . In the latter case, the blood-vessel kynurenine concentration was calculated from the kynurenine concentration in total brain tissue, based on the localization of Ido exclusively in endothelial cells 14, 15, 19 and the percentage of endothelial cells in brain mass (≤1%; ref. 15 ). Nevertheless, we cannot exclude the possibility that a kynurenine derivative or trace contaminant present in the preparation of kynurenine that we purchased was responsible for some of the activities observed, although the commercial kynurenine that we used was pure when examined by nuclear magnetic resonance and mass spectrometry analyses (data not shown). We also considered the possibility that formate, an additional product of Ido action on tryptophan and a heme ligand 32 , might contribute to vessel relaxation.
In contrast to kynurenine, however, formate (≤5 mM) did not relax preconstricted aortic rings (data not shown). Therefore, like the kynurenine metabolites 3-hydroxykynurenine, kynurenic acid, 3-hydroxyanthranilate and quinolinic acid, formate does not seem to participate in the regulation of vascular tone.
Hypotension is a common complication of sepsis and cerebral malaria in humans 2,20 and mice 6, 21 . We observed that pharmacological inhibition of Ido restored normal blood pressure in endotoxemic and malaria-infected wild-type mice and that genetic deletion of Ido1 attenuated the drop in blood pressure in mice challenged with LPS. Of potential clinical relevance, attenuation of hypotension was achieved with Ido inhibition commencing as late as 8 h after induction of endotoxemia. Additionally, pharmacological and genetic blockade of Ido has recently been reported to lower the mortality of mice in response to LPS 33 but not to experimental malaria 34, 35 , although these studies did not investigate a role of Ido in the regulation of blood pressure. However, Ido1 −/− mice still developed hypotension when challenged by either malaria infection or endotoxemia, perhaps reflecting redundancy in blood pressure regulation. For example, mice deficient in heme oxygenase-1 (which generates the vasodilator carbon monoxide) or soluble epoxide hydrolase (which inactivates other vasodilators, namely epoxyeicosatrienoic acids) show normal basal blood pressure 36, 37 . However, both types of mice have an attenuated blood pressure response when challenged with LPS 37, 38 , similar to the situation we observed with Ido1 −/− mice. In the case of heme oxygenase-1-deficient mice, increased expression of endothelin-1 was suggested as a compensatory mechanism 38 , whereas our studies suggest that enhanced Nos2 activity has a compensatory role in Ido1 −/− mice. The latter interpretation seems to conflict with a recent report indicating decreased bioavailability of NO in PbA infection 39 . However, that study 39 examined blood-related parameters of NO bioavailability, whereas our measure of the activity of NO was limited to effects on the vessel wall. Also, we observed an increased contribution Nos2 activity to hypotension only in the case of Ido1 −/− mice, which were not studied in the previous report 39 . Compared with Nos2, the contribution of Ido to the drop in blood pressure in endotoxemic mice is smaller (~30 mm Hg vs. ~10 mm Hg, respectively). However, the relative importance of Ido to Nos2 may be greater in humans, where, compared to mice, Nos2 has a smaller role and Ido activity is more pronounced in the setting of inflammation 11 .
A common thread among NO-modulated processes in the vasculature is their dependence on cGMP production by the heme-containing sGC. Activation of sGC occurs when NO binds heme. We provide direct evidence that kynurenine can activate this pathway, resulting in blood vessel relaxation. Unexpectedly, kynurenine also activated oxidized or heme-free sGC, in sharp contrast to NO, which requires reduced heme to function. Although kynurenine is not a strong activator of oxidized or heme-free sGC, such activation would be expected to cause biologically relevant increases in cGMP. Our findings reveal kynurenine as an endogenous substance capable of activating oxidized or heme-free sGC, raising the possibility that Ido-mediated conversion of tryptophan to kynurenine may represent a 'back-up' system contributing to vessel relaxation in situations where sGC becomes oxidized and heme depleted and, hence, refractory to activation by NO. Indeed, oxidative stress associated with inflammation and vascular disease states leads to a form of sGC that is indistinguishable from the in vitro oxidized, heme-free enzyme, such that oxidized or heme-free sGC is physiologically relevant 29 .
Our work provides a potential therapeutic strategy for the regulation of vascular tone in hypertension, through manipulation of the a r t i c l e s nature medicine VOLUME 16 | NUMBER 3 | MARCH 2010 2 8 5 activity of Ido or the concentrations of tryptophan and kynurenine in the vasculature. We hypothesize that tryptophan metabolism to kynurenine could be crucial in systemic inflammation in humans, perhaps particularly in conditions where NO bioactivity is impaired by dysfunctional sGC.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Physiology. We recorded SBP in conscious mice with a computerized, noninvasive tail-cuff system (BP 2000 Blood Pressure Analysis System, Visitech Systems) that has been shown to give results that correlate closely with intraarterial measurements 41 . For each mouse, we used an initial 10 inflationdeflation cycle to set amplifier and instrument controls. Subsequently, we took the average of ten SBP readings to determine a single-session value. We recorded blood pressure before and 1 h after administration of 1-Me-Trp (Sigma, 200 mg per kg body weight, i.p.). In Figure 2i , we recorded blood pressure before and during the onset of endotoxemia with and without 1-Me-Trp (50 mg per kg body weight, i.p.) administered at 0, 4 and 8 h after injection of LPS. We recorded MAP in the femoral artery of anesthetized spontaneously hypertensive rats before and after intravenous infusion of l-tryptophan, l-kynurenine or sodium nitroprusside (Sigma) to give final blood concentrations ranging from 0.15 mM to 1.5 mM (for kynurenine and tryptophan) and 0.15 µM to 1.5 µM (SNP), with systolic blood pressure being monitored continuously. We assumed a total blood volume of 17 ml for the 250-g rats used. For these experiments, we pretreated the rats with atropine sulfate (Sigma, 0.5 mg per kg body weight intravenously) to block alterations of blood pressure mediated by vagal reflex.
ONLINE METHODS
To measure vascular reactivity, we mounted porcine coronary artery rings isolated from pig hearts obtained from a local abattoir in Krebs buffer (Sigma) in a myobath 42 . After inducing contraction with KCl (25, 50, 100 mM), we constructed the cumulative dose-response curve to the thromboxane A 2 analog U-46619 (Cayman). To measure dilation, we precontracted the rings with U-46619 (30 nM) to ~50-60% of the maximum response. We determined the cumulative dose-response curve to bradykinin (Sigma) expressed as the percentage tension change relative to initial contraction. For experiments with mouse aortas, we mounted the rings in Krebs buffer in a multiwire myograph system (Model 610M, Danish Myo Technology). After inducing contraction with three consecutive additions of KCl (100 mM), we precontracted the rings with norepinephrine (100 nM) to ~50-60% of the maximum KCl response. We then recorded the subsequent response to kynurenine (Fluka).
We repeated the above process with l-NAME (Sigma, 300 µM) and indomethacin (Sigma, 10 µM) to inhibit the activities of endothelial nitric oxide synthase and cyclooxygenase, respectively. Additionally, we used tryptophan (8 mM) or kynurenine (100 µM-3 mM) instead of bradykinin, with or without additional inhibitors. All other conditions were identical to those described above. We allowed the vessels to equilibrate for ≥60 min between exposures to the various agents. As required, we denuded the rings of the endothelium; we confirmed denudation by a lack of vascular response to bradykinin. To downregulate sGC, we preincubated porcine coronary artery rings in Krebs solution at 37 °C for 24 h in the presence or absence (control) of 10 µM ODQ (Sigma).
Cell and tissue culture. We collected endothelial cells from porcine aortas, obtained from a local abattoir, and cultured them with M199 (Invitrogen) 43 . We cultured rat aortic smooth muscle cells (Cell Applications) as previously described 43, 44 . We pretreated confluent cells in the presence of 200 µM tryptophan with various concentrations of porcine IFN-γ (Endogen) as indicated in Figure 3a ,b for 20 h or with 250 ng ml −1 for the time indicated in Figure 3c,d . We isolated human platelet-rich plasma from a healthy male donor (34 years old) with approval from the Human Ethics Committee of the University of New South Wales and informed consent from the subject, and we washed it before use as previously described 45 . For ex vivo induction of Ido, we incubated porcine coronary artery rings at 37 °C in serum-free M-199 medium containing 200 µM tryptophan without and with IFN-γ for up to 24 h. We determined the amount of released kynurenine and calculated its concentration in the coronary lumen, taking into account the ratio of luminal versus medium volumes. For the vessels used for determination of the response to tryptophan (Fig. 4a) , we incubated fresh porcine circumflex arteries with intact or denuded endothelium for 20 h at 37 °C in M199 containing 200 µM tryptophan in the absence or presence of 400 ng ml −1 IFN-γ. We then removed the arteries, washed them and incubated them with 300 µM l-NAME and 10 µM indomethacin for 30 min and preconstricted them with U-46619 to 50-60% of maximum force.
Immunohistochemistry.
We assessed the expression of Ido in arterioles from kidney and intestine collected from mice 5 d (PbA 19 ) or 8 d (PbK) after infection or 48 h after injection with LPS with a rabbit polyclonal antibody to Ido (TransGenic Inc., KAL-KR101) at a concentration of 2.5 µg ml −1 . We blocked endogenous biotin with DakoCytomation Biotin Blocking System (DAKO, X0590) per the manufacturer's instructions before incubation with primary antibody. We used the Negative Control Rabbit Immunoglobin Fraction (DAKO, X0936) instead of the primary antibody to serve as isotype control.
Biochemical analyses.
We assessed Ido activity by the conversion of tryptophan to kynurenine as described previously; we measured tryptophan, kynurenine, 3-hydroxykynurenine, kynurenic acid and 3-hydroxyanthranilic acid concentrations by HPLC 26, 46, 47 . We treated mouse plasma with 5% trichloroacetic acid to precipitate proteins before HPLC analysis of tryptophan and kynurenine.
We assessed the concentrations of cGMP and cAMP in porcine coronary artery homogenates with enzyme immunoassay kits (Cayman Chemical) following the manufacturer's protocols. Prior to homogenization, we incubated arterial rings at 37 °C with the stimulator indicated in Figure 5b and Figure 6b and in the presence of 300 µM l-NAME, 10 µM indomethacin and 100 µM isobutylmethylxanthine (Sigma) (for cGMP and cAMP determination). We purified rat sGC from a baculovirus-Sf9 expression system 48 and measured its activity as previously described 27 . We prepared heme-free rat sGC as previously described 27, 49 . Briefly, we incubated the enzyme with 0.5% Tween-20 for 5 min at 37 °C, which causes loss of the prosthetic heme group. To avoid reconstitution of sGC with heme, we also included Tween-20 in the test assay. We enriched adenylyl cyclase as a membrane preparation 50 from porcine coronary arteries. We assessed its activity in the absence or presence of 1 mM kynurenine or 10 mM NaF (positive control) at 37 °C for 12 min. We purified cAMP by two sequential columns (using 10-ml syringes) containing ~5 ml bed volume of Dowex (Sigma) and neutral alumina oxide (Sigma), respectively, before the assay.
Western blotting. For Ido, we subjected porcine aortic endothelial cell lysates with equal amounts of protein to western blotting 51 . For sGC, we used western blotting of porcine coronary artery homogenates with a rabbit polyclonal antibody to sGC (Alexis Biochemicals, ALX-210-867-1). To assess VASP phosphorylation, we stimulated platelets or MEG-01 cells (generously provided by B.H. Chong) (one volume) with kynurenine (1 and 10 mM) or DEA-NO (Cayman, 300 nM) or forskolin (Sigma, 1 µM) for 3 min at 37 °C, treated them with stopping solution (0.5 volumes of 5% glycerol, 6% SDS, 0.0075% bromophenol blue and 200 mM Tris-HCl, pH 6.8) and subjected the lysates to western blotting with either a rabbit polyclonal antibody to total VASP (M4, AXXORA) or mouse monoclonal antibodies to phospho-Ser157 (nanoTools, NT-0085-100) and phospho-Ser239 VASP (nanoTools, NT-0047-100).
Statistical analyses. Data are expressed as means ± s.e.m. We performed statistical analyses with the Prism statistical program (GraphPad v3.0). We used one-way analysis of variance and the Student-Newman-Keul's test to evaluate differences between groups. We compared dose-response curves by two-way analysis of variance for repeated measures. Otherwise, we used the Mann-Whitney test to evaluate differences between treatments. In all cases, P < 0.05 was considered significant. 
